Patients with MO are insulin resistant and the degree of insulin resistance (IR) further depends on glycemic status. To determine IR, model-based indices use fasting and/or post-challenge glucose and insulin levels. In this study, we examined the validity of indices of GM in a large cohort of patients with MO and varying degrees of glucose tolerance. We included 1337 patients with MO without known diabetes (mean age 40±12 years, mean±SD, BMI 45.0± 6.6kg/m²). All patients underwent a 75g oGTT, glucose and insulin levels were repeatedly measured for the calculation of IR and Insulin Sensitivity indices (Table) and analysis for the respective glucose tolerance categories. Diabetes mellitus (DM) was detected in 120 (9%) patients, 348 (26%) had impaired glucose tolerance or impaired fasting glucose (IGT/IFG), 869 (65%) patients had normal glucose tolerance (NGT). Patients with DM were older (p<0.001) and had a lower BMI (p= 0.014) compared to NGT. GM indices are depicted in the Table. and show that all indices except for Matsuda and AUC insulin show differences between the glucose tolerance categories. In patients with MO, GM indices using basal glucose and insulin levels can be used to routinely measure insulin resistance without need of more elaborate testing. In particular, they can be used in patients with diabetes when an OGTT would be inappropriate.

Disclosure

J. Brix: None. E. Krzizek: None. A. Tura: None. G. Pacini: None. B. Ludvik: Advisory Panel; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Sanofi, Takeda Development Centre Europe Ltd. Research Support; Self; Akebia Therapeutics, Eli Lilly and Company, Novartis AG, Novo Nordisk A/S. Speaker's Bureau; Self; Merck Sharp & Dohme Corp.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.